MV Capital Management
TLX icon

MV Capital Management’s Telix Pharmaceuticals TLX Stock Holding History

MV Capital Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$823 Hold
75
– – ﹤0.01% 949
2026
Q2 		$865 Buy
75
+14
+23% +$143 ﹤0.01% 940
2026
Q1 		$584 Buy
61
+50
+455% +$381 ﹤0.01% 948
2025
Q4 		$83 Buy
+11
New +$106 ﹤0.01% 1123

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Aubrey Capital Management
Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
WoodTrust Financial
WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return
Natixis
Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

MV Capital Management's TLX Position: Q3 2026 in Review

MV Capital Management held its Telix Pharmaceuticals (TLX) position steady in Q3 2026 at 75 shares worth $823. The position accounts for ﹤0.01% of the portfolio, ranked #949.

MV Capital Management first reported a position in TLX in Q4 2025 and has held it in 4 quarters since. The position peaked at $865 in Q2 2026. 34 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

  • MV Capital Management held 75 shares of Telix Pharmaceuticals worth $823 as of Q3 2026.
  • MV Capital Management left its Telix Pharmaceuticals share count unchanged in Q3 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of MV Capital Management's portfolio in Q3 2026, its #949 holding.
  • MV Capital Management first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • MV Capital Management's Telix Pharmaceuticals position peaked at $865 in Q2 2026.
  • 34 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on MV Capital Management's 13F filing for Q3 2026, filed 29 Oct 2026.